Therapeutic area
Ophthalmology biotech companies
The 2 ophthalmology companies we cover, with cash and runway from their latest SEC filings, trial milestones from ClinicalTrials.gov, and FDA decisions from their own 8-Ks. Companies are tagged by the areas their pipelines target.
Companies
| Company | Most advanced program | Cash & investments | Runway | Profile |
|---|---|---|---|---|
| REGNRegeneron Pharmaceuticals | Dupixent · multiple type 2 inflammatory diseasesApproved | $17.82B2026-06-30 | — | archived |
| EYPTEyePoint Pharmaceuticals | EYP-1901 · Diabetic Macular Edema (DME)Phase 3 | $180M2026-06-30 | ~8 mo | maintained |
Runway is cash divided by quarterly operating burn and is not shown for companies funded by their own revenue. Figures and their dates are on each company page, linked to the filing.
Upcoming trial milestones
- 2028-02-07 · REGN · OLYMPIA-1: Odronextamab in Previously untreated follicular lymphoma — primary completion ClinicalTrials.gov
- 2028-06-19 · REGN · Dupilumab paediatric EoE: Dupilumab in Eosinophilic oesophagitis in children — primary completion ClinicalTrials.gov
- 2030-01-18 · REGN · Pozelimab + cemdisiran PNH: Pozelimab and cemdisiran in Paroxysmal nocturnal haemoglobinuria — primary completion ClinicalTrials.gov
A registry milestone is the date data collection is scheduled to end, not the date results are released.
FDA decisions
None of these companies has an FDA decision on our PDUFA calendar, which lists only dates a company has stated in a filing.
Educational information, not investment advice. See where each field comes from.